Regulatory Rapporteur February 2021 | MEMBERS |
Advanced therapies and regenerative medicines regulation – part II: the US | MEMBERS |
Fixed-dose combination products – the regulatory landscape in the US, the EU and its evolution in India | MEMBERS |
Can Chinese Phase I data from the West accelerate China drug development? The science of ethnobridging | MEMBERS |
Industry’s experience on ACSS regulatory worksharing pilot | MEMBERS |
Reliability standards for Japanese marketing approval applications | MEMBERS |
Advertising cosmetics versus medicines: a comparative analysis across markets | MEMBERS |
A review of IDMP and SPOR data management services | MEMBERS |